leisure time -WSS

leisure time

author：knowledge 2025-10-02 03:32:03 - browse：199

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Cancer, immunology, HIV research ensnared in fetal tissue politics

leisure time

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Mirador, a new biotech startup, launches with $400 million

Chinese researcher claims birth of first gene

This gene therapy has record $4.25 million price. It's saved children.

Sen. Bill Cassidy on how to lower drug prices

Drinking water from half of US faucets contains PFAS: Study

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Medical records are filled with copy

The PBM ad wars are taking over Washington, D.C.

Cancer drug shortages should be causing more outrage

House panel to mark up pandemic

What does generative AI mean for health care? We asked experts

With Wegovy coverage, Medicare patients may face high costs

Affirmative action in medical school literally saved lives

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

What does generative AI mean for health care? We asked experts

California man arrested in connection with serial murders of Mexican strip club workers

Wikipedia

Biotech investment managers search for lucrative opportunities

Asbestos ban is immediate, but health effects will linger for decades

Why Titanic fascinates society, still drawing tours to the wreckage

Steward Health Care expansion into Malta flopped

Another man arrested in connection with shooting at Kansas nightclub

Steward Health Care expansion into Malta flopped

Wikipedia

explore

leisure time

leisure time